Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
62 hedge funds and large institutions have $1.18B invested in Kinnate Biopharma Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 18 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
13% more funds holding
Funds holding: 55 → 62 (+7)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
18% less capital invested
Capital invested by funds: $1.43B → $1.18B (-$251M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$31.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.7M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.29M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.96M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$6.66M |
| 4 |
Millennium Management
New York
|
-$3.57M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Wellington Management Group
Boston,
Massachusetts
| – | -$227K | -5,698 | Closed |
|
|
HF
77
HRT Financial
New York
| – | -$223K | -5,617 | Closed |
|
|
PHK
78
Point72 Hong Kong
Hong Kong
| – | -$217K | -5,463 | Closed |
|
79
Rockefeller Capital Management
New York
| – | -$129K | -3,260 | Closed |
|
|
PFO
80
Pathstone Family Office
Englewood,
New Jersey
| – | -$8K | -198 | Closed |
|
KNTE Hedge Fund Activity: Q1 2021 in Review
62 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q1 2021, worth a combined $1.18B — down 18% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KNTE positions and 18 closed out — a net gain of 7 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $31.4M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.
- 62 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q1 2021, up from 55 in Q4 2020.
- Funds reported $1.18B of Kinnate Biopharma Inc. Common Stock stock for Q1 2021, down 18% quarter-over-quarter.
- 25 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q1 2021 and 18 closed out, a net change of +7 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q1 2021 was BlackRock, an estimated $31.4M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q1 2021 was Fidelity Investments, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2021.